SINOPHARM GRP CO. H YC 1 financial statements, including revenue, expenses, and profit
The total revenue of X2S for the last semiannual is 39.08 B EUR, and it's 2.36% higher compared to the previous semiannual. The net income of H2 24 is 451.16 M EUR.